Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain.
Bradykinin
Bradykinin B2 receptor antagonists
Hereditary angioedema
Icatibant
On-demand treatment
Registries
Spain
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
29 12 2021
29 12 2021
Historique:
received:
01
06
2021
accepted:
13
12
2021
entrez:
30
12
2021
pubmed:
31
12
2021
medline:
31
12
2021
Statut:
epublish
Résumé
The Icatibant Outcome Survey (IOS) is an international registry monitoring the use of icatibant, a bradykinin B Descriptive retrospective analyses of data are reported from 10 centers in Spain vs 51 centers in 12 other participating countries (July 2009 to January 2019). No meaningful differences were identified between patients in Spain (n = 119) and patients across other countries (n = 907) regarding median age at symptom onset (15.0 vs 12.0 years) or diagnosis (22.3 vs 20.5 years). Overall HAE attack rates (total attacks/total years of follow-up) were 2.66 in Spain and 1.46 across other countries. Patients in Spain reported fewer severe/very severe HAE attacks before treatment (41.0% vs 45.9%; P < 0.0001) and, for icatibant-treated attacks, longer median time to treatment (2.9 vs 1.0 h), time to attack resolution (18.0 vs 5.5 h), and total attack duration (24.6 vs 8.0 h). Use of androgens for long-term prophylaxis was higher in Spain (51.2% vs 26.7%). Patients with HAE-1/2 in Spain reported fewer severe/very severe attacks, administered icatibant later, and had longer-lasting attacks than did patients across other countries in IOS. These differences may indicate varying disease management practices (e.g., delayed icatibant treatment) and reporting. Efforts to raise awareness on the benefits of early on-demand treatment may be warranted. NCT01034969.
Sections du résumé
BACKGROUND
The Icatibant Outcome Survey (IOS) is an international registry monitoring the use of icatibant, a bradykinin B
METHODS
Descriptive retrospective analyses of data are reported from 10 centers in Spain vs 51 centers in 12 other participating countries (July 2009 to January 2019).
RESULTS
No meaningful differences were identified between patients in Spain (n = 119) and patients across other countries (n = 907) regarding median age at symptom onset (15.0 vs 12.0 years) or diagnosis (22.3 vs 20.5 years). Overall HAE attack rates (total attacks/total years of follow-up) were 2.66 in Spain and 1.46 across other countries. Patients in Spain reported fewer severe/very severe HAE attacks before treatment (41.0% vs 45.9%; P < 0.0001) and, for icatibant-treated attacks, longer median time to treatment (2.9 vs 1.0 h), time to attack resolution (18.0 vs 5.5 h), and total attack duration (24.6 vs 8.0 h). Use of androgens for long-term prophylaxis was higher in Spain (51.2% vs 26.7%).
CONCLUSION
Patients with HAE-1/2 in Spain reported fewer severe/very severe attacks, administered icatibant later, and had longer-lasting attacks than did patients across other countries in IOS. These differences may indicate varying disease management practices (e.g., delayed icatibant treatment) and reporting. Efforts to raise awareness on the benefits of early on-demand treatment may be warranted.
TRIAL REGISTRATION
NCT01034969.
Identifiants
pubmed: 34965883
doi: 10.1186/s13223-021-00641-3
pii: 10.1186/s13223-021-00641-3
pmc: PMC8715569
doi:
Banques de données
ClinicalTrials.gov
['NCT01034969', 'NCT01034969']
Types de publication
Journal Article
Langues
eng
Pagination
137Informations de copyright
© 2021. The Author(s).
Références
Maurer M, Magerl M, Ansotegui I, Aygören-Pürsün E, Betschel S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2017 revision and update. Allergy. 2018;73(8):1575–96.
doi: 10.1111/all.13384
Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94(4):498–503.
doi: 10.1016/S1081-1206(10)61121-0
Zanichelli A, Longhurst HJ, Maurer M, Bouillet L, Aberer W, Fabien V, et al; IOS Study Group. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allergy Asthma Immunol. 2016;117(4):394–8.
Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–74.
doi: 10.1016/j.amjmed.2005.09.064
Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–7.
doi: 10.1016/j.jaci.2012.05.055
Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol. 2013;9:29.
doi: 10.1186/1710-1492-9-29
Zanichelli A, Magerl M, Longhurst HJ, Aberer W, Caballero T, Bouillet L, et al; IOS Study Group. Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey. Clin Transl Allergy. 2018;8:42.
Shire Orphan Therapies. Firazyr (icatibant) injection, for subcutaneous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022150s007lbl.pdf . Accessed 22 Oct 2019.
European Medicines Agency. Firazyr 30 mg solution for injection in pre-filled syringe. https://www.ema.europa.eu/en/documents/product-information/firazyr-epar-product-information_en.pdf . Accessed 22 Oct 2019.
Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G, et al; I O S Investigators. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One. 2013;8(2):e53773.
ClinicalTrials.gov. Firazyr® Patient Registry (Icatibant Outcome Survey —IOS). https://clinicaltrials.gov/ct2/show/NCT01034969. Accessed October 22, 2019.
Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V; I. O. S. Study Group. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol. 2016;26(6):383–6.
Caballero T, Aberer W, Longhurst HJ, Maurer M, Zanichelli A, Perrin A, et al; IOS Study Group. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. J Eur Acad Dermatol Venereol. 2017;31(7):1214–22.
Hernández Fernandez de Rojas D, Ibañez E, Longhurst H, Maurer M, Fabien V, Aberer W, et al; IOS Study Group. Treatment of HAE attacks in the Icatibant Outcome Survey: an analysis of icatibant self-administration versus administration by health care professionals. Int Arch Allergy Immunol. 2015;167(1):21–8.
Gómez-Traseira C, Pérez-Fernandez E, López-Serrano MC, García-Ara MC, Pedrosa M, López-Trascasa M, et al. Clinical pattern and acute and long-term management of hereditary angioedema due to C1-esterase inhibitor deficiency. J Investig Allergol Clin Immunol. 2015;25(5):358–64.
pubmed: 26727765
Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, et al. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol. 2019;15:72.
doi: 10.1186/s13223-019-0376-8
Longhurst HJ, Dempster J, Lorenzo L, Buckland M, Grigoriadou S, Symons C, et al. Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom. Allergy Asthma Clin Immunol. 2018;14:28.
doi: 10.1186/s13223-018-0253-x
Maurer M, Bork K, Martinez-Saguer I, Aygören-Pürsün E, Botha J, Andresen I, et al. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. J Eur Acad Dermatol Venereol. 2019;33(1):163–9.
doi: 10.1111/jdv.15232
Toubi E, Kivity S, Graif Y, Reshef A, Botha J, Andresen I. Icatibant Outcome Survey in patients with hereditary angioedema: experience in Israel compared with other countries. Isr Med Assoc J. 2018;20(4):227–32.
pubmed: 29629730